Rapid Cadence Cycling for Parkinson's Disease: A Study of Implementation and Efficacy in the Community Setting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults age 18 or older.
- Clinically confirmed diagnosis of idiopathic PD by a movement disorder specialist.
- Hoehn and Yahr stage I-III while ON anti-parkinsonian medication.
- Stable or absent MAO-B inhibitors (Selegiline, Rasagiline, Zydis selegiline HCL Oral disintegrating) for at least 60 days prior to enrollment; stable or absent other medications for PD motor symptoms (Levodopa, Dopamine agonists, Anticholinergics, Amantadine, COMT-Inhibitors) for at least 30 days prior to enrollment; stable or absent medications for the following PD-non-motor symptoms: depression, anxiety, cognition, sleep, orthostatic hypotension.
- Agreement to defer any medication changes until after completion of 8-week program and post-test measurements.
- Written permission by a physician to participate in the program.
- English language proficiency sufficient to understand and participate in a cycling class taught in English.
Exclusion Criteria:
- Clinically significant medical disease that would increase the risk of exercise-related complications (eg: cardiac or pulmonary disease, uncontrolled diabetes mellitus, uncontrolled hypertension or stroke) as determined by a treating physician through letter obtained by YMCA or the study investigator.
- Dementia as evidenced by a score of less than 116 on the Mattis Dementia Rating Scale or dementia in the opinion of the study investigator that would prohibit subject from complying with all study activities.
- Other medical or musculoskeletal contraindication to exercise.
- Concurrent participation in another trial of exercise therapy for PD or initiation of a new structured exercise plan during the duration of the study. Note: participants may continue any pre-existing exercise routine (including group-based classes) during the study but will be asked not to start anything new.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Cycling Intervention
Single-arm trial.
All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
|
Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of individuals who complete at least 80% of offered cycling sessions [Tolerability]
Time Frame: assessed at conclusion of the 8 week intervention
|
Investigators will consider those who do not withdraw from the study, are not lost to follow up, and complete at least 80% of the cycling sessions to demonstrate tolerability of the study.
|
assessed at conclusion of the 8 week intervention
|
|
Proportion of subjects reporting an adverse event during class [Safety]
Time Frame: assessed at each class by study staff and weekly by PI for duration of 8 week intervention
|
Safety will be reported descriptively and include the proportion of subjects reporting any adverse event.
|
assessed at each class by study staff and weekly by PI for duration of 8 week intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Unified Parkinson's Disease Rating Scale-section III Motor
Time Frame: Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
The Unified Parkinson's Disease Rating Scale (UPDRS) section III measures severity of motor symptoms of Parkinson's disease with scores ranging from 0 to 199 with higher scores indicating more severe motor symptoms.
This study utilizes a modified version of the UPDRS without rigidity which will be recorded on video and rated remotely by a movement disorder neurologist blinded to intervention status of the participant.
This modified version has been shown to be reliable and valid, both at cross-sectional time points and longitudinally (Abdolahi, 2013).
|
Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
|
Timed Up and Go
Time Frame: Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
The Timed Up and Go test is measured in seconds with a range of 5-25 seconds (longer is worse)
|
Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
|
Trail Making Test A& B
Time Frame: Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
This cognitive test is measured in seconds with a range (part B) of 60-240 seconds (longer is worse).
|
Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
|
PROMIS sf v1.0 Global Health
Time Frame: Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
A 10-item patient reported outcomes scale measuring five domains (physical function, fatigue, pain, emotional distress, social health) and general health perceptions that cut across domains.
Scores can range from 0-100 where higher is better.
|
Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
|
Assessment of Intelligibility of Dysarthria (AIDS)
Time Frame: Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
The Assessment of Intelligibility of Dysarthric Speech is a tool for quantifying single-word intelligibility, sentence intelligibility, and speaking rate.
The outcome is measured as the percent of words that are intelligible, with higher scores being better.
|
Assessed within two weeks prior to start of intervention and within one week after completion of intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Anne-Marie Wills, MD, MPH, Massachusetts General Hospital
- Study Director: Kathleen E McKee, MD, Massacusetts General Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018P001116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.